Creative Diagnostics launches RSV animal model services

Creative Diagnostics has expanded its preclinical testing portfolio with new Respiratory Syncytial Virus animal model services for researchers developing antivirals and vaccines. The offering is aimed at a major gap in hRSV research: animal systems that better predict human infection and treatment outcomes.

Why it matters: - Human respiratory syncytial virus remains a major cause of infant respiratory illness and hospitalization worldwide. - hRSV also drives morbidity in adults and contributes to premature mortality in older adults. - Better animal models can speed preclinical decisions on antivirals, antibodies and vaccines before candidates reach human trials.

What happened: - Creative Diagnostics launched a specialized suite of Respiratory Syncytial Virus Animal Model services. - The company expanded its preclinical testing portfolio to support virology and microbiology research. - The services are designed for biopharmaceutical and academic researchers working on small-molecule antivirals, therapeutic antibodies and vaccine candidates.

The details: - Creative Diagnostics said the models are intended to address host specificity challenges in human RSV research. - The company identified cotton rat and mouse models as examples of systems it can select based on the infection being studied and the research hypothesis. - The service package includes study design and execution. - The package also includes pathological analysis, immune response profiling, in vivo pharmacokinetic studies and pharmacodynamic, efficacy and toxicity assessments. - Creative Diagnostics said the models can be used to evaluate vaccine immunogenicity and efficacy in preclinical studies. - The services can also support studies of pathogenic mechanisms, new therapeutic targets, antiviral compounds and immunomodulators. - Creative Diagnostics said hRSV animal models are useful for studying RSV infection dynamics, testing therapeutics and developing vaccines. - The company said non-human primates other than chimpanzees are only partially susceptible to hRSV replication. - The company said other commonly used animal models, including cotton rats, mice, ferrets, guinea pigs, hamsters, chinchillas and newborn lambs, also show only partial susceptibility. - Creative Diagnostics said mice and cotton rats remain important for monoclonal antibody prophylaxis work in high-risk infants and for studying RSV immunology and pathogenesis. - The company is headquartered in New York and works as a consulting and experimental service provider focused on virology and microbiology. - More information is available in the company's announcement.

Between the lines: - The launch reflects continued demand for preclinical systems that better bridge the gap between animal studies and human RSV outcomes. - The emphasis on multiple model types suggests Creative Diagnostics is positioning the service as customizable rather than one-size-fits-all. - The release frames RSV work as an area where model choice can materially affect whether candidates advance toward clinical trials.

What's next: - Researchers developing RSV vaccines, antivirals and immunomodulators can use the new services for preclinical screening and package-level assessment. - Creative Diagnostics is likely to market the offering alongside its broader virology portfolio as RSV candidate development continues. - The most immediate impact will be on study planning, model selection and early go/no-go decisions for programs targeting high-risk populations.